top biopharmaceuticals for glp-1 medication Shortages improve Lilly's weight loss drugs, bumping sales forecast by $3bn Eli Lilly Overtakes Novo Nordisk

There is a strong interest in developing obesity treatments based on glucagon-like peptide-1 (GLP-1) agonists, which have proved to limit morbidity and mortality in type 2 diabetes

On December 14th, Merck announced that, within three years, the combination of Keytruda with the mRNA vaccine mRNA-4157 (V940) can reduce the risk of recurrence by nearly half in patients with cutaneous melanoma

amycretin Novo Nordisk, which makes Wegovy and Ozempic, is testing this experimental, unimolecular drug to target two hormone pathways, GLP-1 and amylin, a hormone that helps control hunger

Empower your strategic planning: Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in Glucagon-like peptide-1 agonists market

Behind the scenes the market leans on active pharmaceutical ingredients, peptide synthesis technologies, biologic manufacturing processes, and better drug delivery systems that keep the effect stable

Figure 5